Environmental

STAA’s 11.2% R&D-to-revenue intensity supports product innovation and longer-cycle efficiency, comparing favorably with peers that underinvest in clinical and device development.

Low leverage, with debt-to-equity at 0.10 and net debt negative versus EBITDA, reduces financing pressure and limits balance-sheet-driven environmental tradeoffs versus peers.

High gross margin suggests efficient resource use in manufacturing and commercialization, which can lower waste intensity relative to less efficient medtech peers.

No disclosed environmental controversies or heavy carbon-intensive operations are evident in the provided metrics, leaving STAA’s environmental profile broadly cleaner than many industrial peers.

Social

STAA’s elevated R&D spend indicates sustained investment in product quality and patient outcomes, which is a stronger social signal than peers focused mainly on cost control.

The company’s low stock-based compensation at 8.3% of revenue suggests comparatively restrained dilution, supporting a more balanced employee-value proposition than many growth-stage peers.

Strong gross profitability can support training, service quality, and customer support resources, improving stakeholder experience relative to peers with tighter operating headroom.

No material labor, safety, or product-responsibility controversies are indicated in the supplied data, so STAA appears socially steadier than peers with recurring incidents.

Governance

Debt-to-equity of 0.10 indicates conservative capital structure management, which usually aligns with more disciplined governance than peers carrying heavier leverage.

Negative net debt to EBITDA suggests ample liquidity flexibility, reducing refinancing risk and the governance strain often seen in more levered medtech peers.

Stock-based compensation at 8.3% of revenue is meaningful but not excessive, implying compensation discipline that is better than peers with more aggressive equity issuance.

The provided metrics do not show governance red flags such as balance-sheet stress or weak capital allocation, supporting a solid but not leading governance profile.

Overall Score

STAA screens as a strong ESG relative to peers, led by disciplined capital structure and sustained R&D investment, with no material adverse signals in the provided data.

Score Driver: Conservative Leverage Combined With Sustained Innovation Investment Versus Peers.